TABLE 3.

Clinical application of anti-anginal drugs in patients with HF and T2DM.

Drug	Clinical application						References
	Clinic types of experiments	Patients	Number of examinees (n)	Drug usage and dosage	Usage time	Main results and conclusion
Trimetazidine	A meta-analysis of randomized controlled trials	Patients with chronic HF	n = 994; TMZ therapy group (n = 80), placebo therapy group (n = 76)	/	/	Treatment with TMZ also resulted in significant decrease in LVESV, LVEDV, hospitalization for cardiac causes, and B-type natriuretic peptide. However, there were no significant differences in exercise duration and all-cause mortality between patients treated with TMZ and placebo.	Zhou et al. (2014)
	A prospective, single-blind and single-center study	HF patients	n = 87; TMZ therapy group (n = 51), placebo therapy group (n = 36)	p.o., 20 mg t.i.d.	3 months	Compared to placebo, increments in LVEF and myocardial velocities were significantly higher with TMZ. An increase in LVEF with TMZ was significantly correlated with the presence of DM. It is suggested that addition of trimetazidine to current treatment of HF, especially for those who are diabetic, may improve LV and RV functions.	Gunes et al. (2009)
	A prospective, observational, non-interventional, open-label clinical study	Patients with stable angina pectoris and T2DM	n = 737	p.o., 35 mg t.i.d. Patients with moderate renal impairment received TMZ 35 mg q.d.	6 months	TMZ treatment significantly improved glucose metabolism, lowered HbA1c and glucose levels, and decreased arterial stiffness. In most patients, the tolerability of trimetazidine was rated as excellent to good, with a low incidence of adverse events.	Meiszterics et al. (2017)